U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H19N3O.ClH
Molecular Weight 329.824
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ONDANSENTRON HYDROCHLORIDE, S-

SMILES

Cl.CN1C2=C(C3=C1C=CC=C3)C(=O)[C@H](CN4C=CN=C4C)CC2

InChI

InChIKey=MKBLHFILKIKSQM-ZOWNYOTGSA-N
InChI=1S/C18H19N3O.ClH/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2;/h3-6,9-10,13H,7-8,11H2,1-2H3;1H/t13-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C18H19N3O
Molecular Weight 293.363
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

PubMed

PubMed

TitleDatePubMed
IgE-mediated allergy to granisetron and safe use of ondansetron.
2001-12
Serotonin localization in Phallusia mammillata larvae and effects of 5-HT antagonists during larval development.
2001-12
Analgesic efficacy of tramadol if coadministered with ondansetron.
2001-12
Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis.
2001-12
Central antiemetic effects of AS-8112, a dopamine D2, D3, and 5-HT(3) receptor antagonist, in ferrets.
2001-11-23
Pharmacological characterization of cyclosporine A-induced kaolin intake in rats.
2001-11-10
Radiation-induced emesis: a problem with many open questions.
2001-11-06
Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.
2001-11-02
Failure of ondansetron in treating cerebellar tremor in MS patients--an open-label pilot study.
2001-11
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy.
2001-10-19
Anaphylactic reaction to ondansetron.
2001-10-08
[Postoperative nausea--still a problem].
2001-10-03
Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia.
2001-10-02
[Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in gynecological cancer patients on cisplatin].
2001-10
Treatment of bulimia nervosa with ondansetron.
2001-10
Drug-induced amnesia is a separate phenomenon from sedation: electrophysiologic evidence.
2001-10
Acupuncture versus ondansetron in the prevention of postoperative vomiting. A study of children undergoing dental surgery.
2001-10
Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro.
2001-10
Intestinal serotonin acts as paracrine substance to mediate pancreatic secretion stimulated by luminal factors.
2001-10
Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy.
2001-09
Gender discrepancy observed between chemotherapy-induced emesis and hiccups.
2001-09
Comparing the efficacy of prophylactic metoclopramide, ondansetron, and placebo in cesarean section patients given epidural anesthesia.
2001-09
Effect of ondansetron pretreatment on pain after rocuronium and propofol injection: a randomised, double-blind controlled comparison with lidocaine.
2001-09
Prophylactic ondansetron does not improve patient satisfaction in women using PCA after Caesarean section.
2001-09
Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac.
2001-08-18
Antagonism of the 5-HT(3) receptor does not alter isoflurane MAC in rats.
2001-08
Does the alcoholic's remedy come in a pill?
2001-08
Delayed nausea and vomiting in children receiving antineoplastics.
2001-08
Postoperative nausea and vomiting in female patients.
2001-08
Ondansetron attenuates CCK induced satiety and c-fos labeling in the dorsal medulla.
2001-08
Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo.
2001-08
Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
2001-07
Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
2001-07
Effects of HSP-117, a novel tachykinin NK1-receptor antagonist, on cisplatin-induced pica as a new evaluation of delayed emesis in rats.
2001-07
[Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in lung cancer patients on cisplatin].
2001-07
Outpatient laparoscopic adrenalectomy in patients with Conn's syndrome.
2001-06
Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions.
2001-06
Efficacy of single-dose intravenous dolasetron versus ondansetron in the prevention of postoperative nausea and vomiting.
2001-06
Role of various types of serotonin receptors in regulation of drinking behavior and salt appetite in vasopressin-deficient brattleboro rats.
2001-05
The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism.
2001-04
Prevention of vomiting after general anesthesia for pediatric ophthalmic surgery.
2001-02
Dexamethasone is a cost-effective alternative to ondansetron in preventing PONV after paediatric strabismus repair.
2001-01
Pruritus.
2001
Prevention of vomiting after strabismus surgery in children: dexamethasone alone versus dexamethasone plus low-dose ondansetron.
2001
The neuropharmacology of upper airway motor control in the awake and asleep states: implications for obstructive sleep apnoea.
2001
Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation.
2001
Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders.
2001
Combination of transcutaneous electrical nerve stimulation and ondansetron in preventing cisplatin-induced emesis.
2001
[Postoperative nausea and vomiting--still a problem?].
2001
Ondansetron: a review of its use as an antiemetic in children.
2001
Patents
Substance Class Chemical
Created
by admin
on Wed Apr 02 12:40:17 GMT 2025
Edited
by admin
on Wed Apr 02 12:40:17 GMT 2025
Record UNII
RJ5EJS99VH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
4H-CARBAZOL-4-ONE, 1,2,3,9-TETRAHYDRO-9-METHYL-3-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)-, MONOHYDROCHLORIDE, (S)-
Preferred Name English
ONDANSENTRON HYDROCHLORIDE, S-
Common Name English
Code System Code Type Description
CAS
146475-23-2
Created by admin on Wed Apr 02 12:40:17 GMT 2025 , Edited by admin on Wed Apr 02 12:40:17 GMT 2025
PRIMARY
PUBCHEM
57501259
Created by admin on Wed Apr 02 12:40:17 GMT 2025 , Edited by admin on Wed Apr 02 12:40:17 GMT 2025
PRIMARY
FDA UNII
RJ5EJS99VH
Created by admin on Wed Apr 02 12:40:17 GMT 2025 , Edited by admin on Wed Apr 02 12:40:17 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE